Oct 27, 2025 06:50AM Reviva Pharmaceuticals (RVPH) PT Lowered to $4 at H.C. Wainwright

Oct 9, 2025 05:37AM Increasing unusual call option volume: RVPH POET IE COTY SLNO TMQ NPWR FBL ARBE

Oct 8, 2025 09:46AM Increasing unusual call option volume: RVPH POET RC TMQ ICE PLG SGOL LAZR CRML ARBE SLI FE OVID

Oct 8, 2025 06:18AM Increasing unusual option volume: RVPH TMQ TIGO LAR POET GSM XLI ACVA WWR FE SES

Oct 6, 2025 04:37AM Increasing unusual call option volume: OVID RVPH ARBE MLTX LAC BFLY BLDP PLUG

Sep 29, 2025 05:59AM Chardan Capital Markets Starts Reviva Pharmaceuticals (RVPH) at Buy, PT $2

Sep 15, 2025 09:04AM Reviva Pharmaceuticals (RVPH) PT Lowered to $7 at Benchmark as Additional Capital Likely Required

Aug 14, 2025 05:48PM Reviva Pharmaceuticals Holdings, Inc. (RVPH) Tops Q2 EPS by 1c

Jun 26, 2025 08:41AM Reviva Pharmaceuticals (RVPH) Prices 20M Share Offering at $0.50/sh

Jun 25, 2025 04:18PM Reviva Pharmaceuticals (RVPH) Announces Proposed Public Offering of Common Stock, Warrants

Jun 2, 2025 07:02AM Reviva Pharmaceuticals (RVPH) Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 30, 2025 04:13PM Reviva Pharmaceuticals (RVPH) Enters $50M ATM Offering

May 23, 2025 07:48AM Benchmark Reiterates Speculative Buy Rating on Reviva Pharmaceuticals (RVPH)

May 20, 2025 07:02AM Reviva Pharmaceuticals (RVPH) PT Lowered to $3 at D. Boral Capital

May 15, 2025 07:00PM Reviva Pharmaceuticals Holdings, Inc. (RVPH) Tops Q1 EPS by 8c

Apr 9, 2025 09:33AM Reviva Pharmaceuticals (RVPH) PT Lowered to $14 at Benchmark

Mar 31, 2025 04:12PM Reviva Pharmaceuticals Holdings, Inc. (RVPH) Reports FY24 results

Jan 10, 2025 10:39AM Maxim Group Upgrades Reviva Pharmaceuticals (RVPH) to Buy

Jan 10, 2025 09:00AM Roth/MKM Starts Reviva Pharmaceuticals (RVPH) at Buy

Dec 20, 2024 07:01AM Applied Therapeutics Inc. (APLT) Appoints John H. Johnson as Executive Chairman

Dec 16, 2024 05:20PM Reviva Pharmaceuticals (RVPH) Announces Proposed Share Offering

Dec 16, 2024 08:05AM Reviva Pharmaceuticals (RVPH) Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

Nov 12, 2024 08:06AM Reviva Pharmaceuticals (RVPH) Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Sep 23, 2024 07:06AM EF Hutton Starts Reviva Pharmaceuticals (RVPH) at Buy

Sep 9, 2024 08:04AM Reviva Pharmaceuticals (RVPH) Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Aug 21, 2024 06:17AM Reviva Pharmaceuticals (RVPH) Prices 4.76M Share Offering at $1.05/sh

Aug 15, 2024 04:46PM Reviva Pharmaceuticals Holdings, Inc. (RVPH) Tops Q2 EPS by 4c

Aug 6, 2024 08:02AM Reviva Pharmaceuticals (RVPH) Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

Jul 11, 2024 10:33AM H.C. Wainwright Reiterates Buy Rating on Reviva Pharmaceuticals (RVPH)

Jul 9, 2024 08:12AM Reviva (RVPH) Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Jun 11, 2024 06:41AM Reviva Pharmaceuticals (RVPH) PT Lowered to $14 at H.C. Wainwright